



2 August 2022

MICHAEL ALDRIDGE RESIGNS AS CEO

Continues as non-executive director

MELBOURNE, AUSTRALIA (2 August 2022): Hexima Limited (ASX:HXL), a clinical stage biotechnology company, today announces that Mr Michael Aldridge, its Managing Director & CEO, will resign his executive responsibilities effective immediately. Nicole van der Weerden, currently Chief Operating Officer, will serve as acting CEO. Mr Aldridge will continue as a non-executive director of the Company.

This step is consistent with Hexima's previously announced intention to manage expenses associated with non-essential employees in a cost effective and orderly manner. Mr Aldridge will not be remunerated for his role as non-executive director.

This announcement is authorised for release to ASX by Nicole van der Weerden, Acting CEO & Director

Enquiries:

Dr Nicole van der Weerden
Acting Chief Executive Officer
n.vanderweerden@hexima.com.au

To join our email database and receive company announcements please [click here](#)